The litigation centers on a period between August 1, 2025, and May 15, 2026, during which Regeneron’s stock reached a high of $731.77. Plaintiffs contend that Ryan Crowe, the company’s Senior Vice President of Investor Relations, provided misleading commentary regarding the oncology trial’s progression-free survival rates. According to the complaint, these communications obscured the statistical risks posed by a slowing event rate, creating a false impression of clinical success that ultimately failed to materialize.
Regeneron Faces Securities Class Action Over Failed Clinical Trial Data
A federal class action lawsuit now challenges Regeneron Pharmaceuticals over alleged misrepresentations regarding its Phase III Fianlimab-Libtayo study. The filing claims that investor-facing statements from company leadership artificially inflated stock prices before a sharp 13.95% decline in May 2026, leaving shareholders to grapple with significant financial losses.
Following an after-market announcement on May 15, 2026, confirming the trial did not meet its primary endpoint, Regeneron shares dropped to $629.68—a loss of $102.09 per share. The suit, filed in the United States District Court for the Southern District of New York, alleges violations of Sections 10(b) and 20(a) of the Exchange Act. Investors who suffered financial harm during the specified window have until September 14, 2026, to apply for lead plaintiff status as the firm Levi & Korsinsky, LLP coordinates the legal effort.
Comments (0)
No comments yet. Be the first!